International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Amgen Announced the United States Food and Drug Administration (FDA) Approval of AMJEVITA™

Psoriasis News Amgen Blog Graphic

Amgen announced the United States Food and Drug Administration (FDA) approval of AMJEVITA™ for treating adults with plaque psoriasis and psoriatic arthritis. AMJEVITA™ is a biosimilar to Humira® and the first of several other biosimilars expected to be approved later this year. AMJEVITA is citrate-free and will be available in prefilled syringe and autoinjector presentations.


Recent Posts

IPC 2023 Think Tank Meeting Report Published in JID Innovations

Improving Medical Adherence in Psoriasis Treatments

Shining a Spotlight: Catching up with 2018 IPC Fellow Filip Rob, MD, PhD

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.